Stent Implantation in Saphenous Vein Grafts

American Journal of Cardiology

Volumn 103, Issue 7, 2009, Pages 1042-1043

  Lozano, Iñigo ^a   Avanzas, Pablo ^a   Rondan, Juan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN;

ANGIOGRAPHY; BARE METAL STENT; DRUG ELUTING STENT; HUMAN; LETTER; PRIORITY JOURNAL; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; SURVIVAL; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

BLOOD VESSEL PROSTHESIS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; PROSTHESIS DESIGN; REOPERATION; SAPHENOUS VEIN;

EID: 62849116477     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.351     Document Type: Letter

References (10)

1. Jim M.H., Ho H.H., Ko R.L., Yiu K.H., Siu C.W., Lau C.P., and Chow W.H. Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) study. Am J Cardiol 103 (2009) 199-202
2. Vermeersch P., Agostoni P., Verheye S., Van Den H.P., Convens C., Bruining N., Van Den B.F., and Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol 48 (2006) 2423-2431
3. Vermeersch P., Agostoni P., Verheye S., Van Den H.P., Convens C., Van Den B.F., and Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 50 (2007) 261-267
4. Bansal D., Muppidi R., Singla S., Sukhija R., Zarich S., Mehta J.L., and Sachdeva R. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 71 (2008) 58-61
5. Hoffmann R., Pohl T., Koster R., Blindt R., Boeckstegers P., and Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 93 (2007) 331-334
6. Pucelikova T., Mehran R., Kirtane A.J., Kim Y.H., Fahy M., Weisz G., Lansky A.J., Moussa I., Gray W.A., Collins M.B., et al. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol 101 (2008) 63-68
7. Ge L., Iakovou I., Sangiorgi G.M., Chieffo A., Melzi G., Cosgrave J., Montorfano M., Michev I., Airoldi F., Carlino M., et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 45 (2005) 989-994
8. Lee M.S., Shah A.P., Aragon J., Jamali A., Dohad S., Kar S., and Makkar R.R. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 66 (2005) 507-511
9. Price M.J., Sawhney N., Kao J.A., Madrid A., Schatz R.A., and Teirstein P.S. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 65 (2005) 208-211
10. Lozano I., Garcia-Camarero T., Carrillo P., Baz J.A., de la Torre Hernandez J.M., Lopez-Palop R., Pinar E., Salvatella N., Avanzas P., and Valdes M. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol 62 (2009) 39-47